Skip to main content
SpringerLink
Log in

The role of 68Ga-Pentixafor PET in multiple myeloma

  • Systematic Review
  • Published:
Clinical and Translational Imaging Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study is to investigate the role of 68Ga-Pentixafor PET in multiple myeloma (MM) by comparing the diagnostic efficacy of 68Ga-Pentixafor PET and 18F-FDG PET and their correlation with clinical features and laboratory results.

Methods

A systematic search of PubMed and Embase databases for included studies reporting 68Ga-Pentixafor PET assessment of MM was performed with a search time frame of build to 2022-12-26. The diagnostic test evaluation tool QUADAS-2 was used to evaluate the quality of the included literature and to perform a descriptive analysis of relevant outcome indicators.

Results

A total of eight studies with a total of 258 patients were included. One study analyzed the diagnostic efficacy of PET and one study only analyzed the correlation of semi-quantitative parameters of PET with clinical features and laboratory results. The remaining six studies analyzed the diagnostic efficacy of PET and the correlation of its semi-quantitative parameters with clinical features and laboratory findings.

Conclusion

There is very limited literature on the clinical application of 68Ga-Pentixafor PET in MM patients, and this study provides a preliminary idea for the use of 68Ga-Pentixafor PET in MM patients. Although 68Ga-Pentixafor PET cannot yet be used as an alternative imaging modality to 18F-FDG PET in MM patients, 68Ga-Pentixafor may represent a valuable molecular probe for non-invasive assessment of CXCR4 expressed by tumor cells, and thus more prospective trials may be needed in the future to further explore the potential of 68Ga -Pentixafor PET in MM imaging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The authors confirm that the data supporting the findings of this study are available within the article.

References

  1. van de Donk NWCJ, Pawlyn C, Yong KL (2021) Multiple myeloma. Lancet 397(10272):410–427. https://doi.org/10.1016/S0140-6736(21)00135-5

    Article  PubMed  Google Scholar 

  2. Terpos E, Dimopoulos MA, Moulopoulos LA (2016) The role of imaging in the treatment of patients with multiple myeloma in 2016. Am Soc Clin Oncol Educ Book. https://doi.org/10.1200/EDBK_159074

    Article  PubMed  Google Scholar 

  3. Lecouvet FE, Vekemans MC, Van Den Berghe T, Verstraete K, Kirchgesner T, Acid S, Malghem J, Wuts J, Hillengass J, Vandecaveye V, Jamar F, Gheysens O, Vande Berg BC (2022) Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT. Skeletal Radiol 51(1):59–80. https://doi.org/10.1007/s00256-021-03841-5

    Article  PubMed  Google Scholar 

  4. von Hinten J, Kircher M, Dierks A, Pfob CH, Higuchi T, Pomper MG et al (2022) Molecular imaging in multiple myeloma—novel PET radiotracers improve patient management and guide therapy. Front Nucl Med 2:801792. https://doi.org/10.3389/fnume.2022.801792

    Article  Google Scholar 

  5. Cassou-Mounat T, Balogova S, Nataf V, Calzada M, Huchet V, Kerrou K, Devaux JY, Mohty M, Talbot JN, Garderet L (2016) 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. Eur J Nucl Med Mol Imaging 43(11):1995–2004. https://doi.org/10.1007/s00259-016-3392-7

    Article  PubMed  CAS  Google Scholar 

  6. Dankerl A, Liebisch P, Glatting G, Friesen C, Blumstein NM, Kocot D, Wendl C, Bunjes D, Reske SN (2007) Multiple myeloma: molecular imaging with 11C-methionine PET/CT–initial experience. Radiology 242(2):498–508. https://doi.org/10.1148/radiol.2422051980

    Article  PubMed  Google Scholar 

  7. Lapa C, Knop S, Schreder M, Rudelius M, Knott M, Jörg G, Samnick S, Herrmann K, Buck AK, Einsele H, Lückerath K (2016) 11C-methionine-PET in multiple myeloma: correlation with clinical parameters and bone marrow involvement. Theranostics 6(2):254–261. https://doi.org/10.7150/thno.13921

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Lapa C, Garcia-Velloso MJ, Lückerath K, Samnick S, Schreder M, Otero PR, Schmid JS, Herrmann K, Knop S, Buck AK, Einsele H, San-Miguel J, Kortüm KM (2017) 11C-methionine-PET in multiple myeloma: a combined study from two different institutions. Theranostics 7(11):2956–2964. https://doi.org/10.7150/thno.20491

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Ho CL, Chen S, Leung YL, Cheng T, Wong KN, Cheung SK, Liang R, Chim CS (2014) 11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT. J Nucl Med 55(5):749–752. https://doi.org/10.2967/jnumed.113.131169

    Article  PubMed  CAS  Google Scholar 

  10. Lapa C, Hänscheid H, Kircher M, Schirbel A, Wunderlich G, Werner RA, Samnick S, Kotzerke J, Einsele H, Buck AK, Wester HJ, Grigoleit GU (2019) Feasibility of CXCR4-directed radioligand therapy in advanced diffuse large B-cell lymphoma. J Nucl Med 60(1):60–64. https://doi.org/10.2967/jnumed.118.210997

    Article  PubMed  CAS  Google Scholar 

  11. Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Hänscheid H, Lückerath K, Schreder M, Bluemel C, Knott M, Keller U, Schirbel A, Samnick S, Lassmann M, Kropf S, Buck AK, Einsele H, Wester HJ, Knop S (2016) First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive Intra- and extramedullary disease. J Nucl Med 57(2):248–251. https://doi.org/10.2967/jnumed.115.167361

    Article  PubMed  CAS  Google Scholar 

  12. Lapa C, Herrmann K, Schirbel A, Hänscheid H, Lückerath K, Schottelius M, Kircher M, Werner RA, Schreder M, Samnick S, Kropf S, Knop S, Buck AK, Einsele H, Wester HJ, Kortüm KM (2017) CXCR4-directed endoradiotherapy induces high response rates in extramedullary relapsed multiple myeloma. Theranostics 7(6):1589–1597. https://doi.org/10.7150/thno.19050

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Buck AK, Haug A, Dreher N, Lambertini A, Higuchi T, Lapa C, Weich A, Pomper MG, Wester HJ, Zehndner A, Schirbel A, Samnick S, Hacker M, Pichler V, Hahner S, Fassnacht M, Einsele H, Serfling SE, Werner RA (2022) Imaging of C-X-C motif chemokine receptor 4 expression in 690 patients with solid or hematologic neoplasms using 68Ga-Pentixafor PET. J Nucl Med 63(11):1687–1692. https://doi.org/10.2967/jnumed.121.263693

    Article  PubMed  CAS  Google Scholar 

  14. Vag T, Gerngross C, Herhaus P, Eiber M, Philipp-Abbrederis K, Graner FP, Ettl J, Keller U, Wester HJ, Schwaiger M (2016) First experience with chemokine receptor CXCR4-targeted PET imaging of patients with solid cancers. J Nucl Med 57(5):741–746. https://doi.org/10.2967/jnumed.115.161034

    Article  PubMed  CAS  Google Scholar 

  15. Werner RA, Kircher S, Higuchi T, Kircher M, Schirbel A, Wester HJ, Buck AK, Pomper MG, Rowe SP, Lapa C (2019) CXCR4-directed imaging in solid tumors. Front Oncol 9:770. https://doi.org/10.3389/fonc.2019.00770

    Article  PubMed  PubMed Central  Google Scholar 

  16. Buck AK, Serfling SE, Lindner T, Hänscheid H, Schirbel A, Hahner S, Fassnacht M, Einsele H, Werner RA (2022) CXCR4-targeted theranostics in oncology. Eur J Nucl Med Mol Imaging 49(12):4133–4144. https://doi.org/10.1007/s00259-022-05849-y

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Mayerhoefer ME, Archibald SJ, Messiou C, Staudenherz A, Berzaczy D, Schöder H (2020) MRI and PET/MRI in hematologic malignancies. J Magn Reson Imaging 51(5):1325–1335. https://doi.org/10.1002/jmri.26848

    Article  PubMed  Google Scholar 

  18. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM (2011) QUADAS-2 Group. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155(8):529–536. https://doi.org/10.7326/0003-4819-155-8-201110180-00009

    Article  PubMed  Google Scholar 

  19. Kraus S, Klassen P, Kircher M, Dierks A, Habringer S, Gäble A, Kortüm KM, Weinhold N, Ademaj-Kospiri V, Werner RA, Schirbel A, Buck AK, Herhaus P, Wester HJ, Rosenwald A, Weber WA, Einsele H, Keller U, Rasche L, Lapa C (2022) Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis. Theranostics 12(13):5986–5994. https://doi.org/10.7150/thno.75847

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Shekhawat AS, Singh B, Malhotra P, Watts A, Basher R, Kaur H, Hooda M, Radotra BD (2022) Imaging CXCR4 receptors expression for staging multiple myeloma by using 68Ga-Pentixafor PET/CT: comparison with 18F-FDG PET/CT. Br J Radiol 95(1136):20211272. https://doi.org/10.1259/bjr.20211272

    Article  PubMed  PubMed Central  Google Scholar 

  21. Kuyumcu S, Isik EG, Tiryaki TO, Has-Simsek D, Sanli Y, Buyukkaya F, Özkan ZG, Kalayoglu-Besisik S, Unal SN (2021) Prognostic significance of 68Ga-Pentixafor PET/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET/CT and laboratory results. Ann Nucl Med 35(10):1147–1156. https://doi.org/10.1007/s12149-021-01652-1

    Article  PubMed  CAS  Google Scholar 

  22. Zhou X, Dierks A, Kertels O, Kircher M, Schirbel A, Samnick S, Buck AK, Knorz S, Böckle D, Scheller L, Messerschmidt J, Barakat M, Kortüm KM, Rasche L, Einsele H, Lapa C (2020) 18F-FDG, 11C-methionine, and 68Ga-Pentixafor PET/CT in patients with smoldering multiple myeloma: imaging pattern and clinical features. Cancers (Basel) 12(8):2333. https://doi.org/10.3390/cancers12082333

    Article  PubMed  CAS  Google Scholar 

  23. Pan Q, Cao X, Luo Y, Li J, Feng J, Li F (2020) Chemokine receptor-4 targeted PET/CT with 68Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 47(3):537–546. https://doi.org/10.1007/s00259-019-04605-z

    Article  PubMed  CAS  Google Scholar 

  24. Ozkan E, Soydal C, Sahin U, Beksac M, Kucuk ON (2020) Evaluation of chemokine receptor-4 expression by 68ga – Pentixafor pet/ct in patients with multiple myeloma. Int J Hematol Oncol 31(4):210–218. https://doi.org/10.4999/uhod.193630

    Article  Google Scholar 

  25. Lapa C, Schreder M, Schirbel A, Samnick S, Kortüm KM, Herrmann K, Kropf S, Einsele H, Buck AK, Wester HJ, Knop S, Lückerath K (2017) [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - comparison to [18F]FDG and laboratory values. Theranostics 7(1):205–212. https://doi.org/10.7150/thno.16576

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lückerath K, Pietschmann E, Habringer S, Gerngroß C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Götze K, Wester HJ, Keller U (2015) In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med 7(4):477–487. https://doi.org/10.15252/emmm.201404698

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Hillengass J, Moulopoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, Drake M, Rajkumar SV, Oestergaard B, Abildgaard N, Hinge M, Plesner T, Suehara Y, Matsue K, Withofs N, Caers J, Waage A, Goldschmidt H, Dimopoulos MA, Lentzsch S, Durie B, Terpos E (2017) Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J 7(8):e599. https://doi.org/10.1038/bcj.2017.78

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Singh J, Fairbairn KJ, Williams C, Das-Gupta EP, Russell NH, Byrne JL (2007) Expert radiological review of skeletal surveys identifies additional abnormalities in 23% of cases: further evidence for the value of myeloma multi-disciplinary teams in the accurate staging and treatment of myeloma patients. Br J Haematol 137:172–173. https://doi.org/10.1111/j.1365-2141.2007.06536.x

    Article  PubMed  Google Scholar 

  29. Wahlin A, Holm J, Osterman G, Norberg B (1982) Evaluation of serial bone X-ray examination in multiple myeloma. Acta Med Scand 212(6):385–387. https://doi.org/10.1111/j.0954-6820.1982.tb03234.x

    Article  PubMed  CAS  Google Scholar 

  30. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, Tosi P, Tacchetti P, Cangini D, Perrone G, Ceccolini M, Brioli A, Buttignol S, Fanin R, Salizzoni E, Baccarani M, Fanti S, Cavo M (2007) A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 92(1):50–55. https://doi.org/10.3324/haematol.10554

    Article  PubMed  Google Scholar 

  31. Pan Q, Luo Y, Cao X, Li J, Li F (2023) 68Ga-Pentixafor PET/CT may fail to detect recurrent multiple myeloma with extramedullary disease. Diagnostics (Basel) 13(5):871. https://doi.org/10.3390/diagnostics13050871

    Article  PubMed  Google Scholar 

  32. Wester HJ, Keller U, Schottelius M, Beer A, Philipp-Abbrederis K, Hoffmann F, Šimeček J, Gerngross C, Lassmann M, Herrmann K, Pellegata N, Rudelius M, Kessler H, Schwaiger M (2015) Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics 5(6):618–630. https://doi.org/10.7150/thno.11251

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

Thanks to all the authors who have contributed to this research.

Funding

There is no funding source for this study.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People’s Republic of China

    Min Wang, Liyi Liu, Jia Wang & Chunyin Zhang

  2. Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, People’s Republic of China

    Min Wang, Liyi Liu, Jia Wang & Chunyin Zhang

  3. Academician (Expert) Workstation of Sichuan Province, Luzhou, Sichuan, People’s Republic of China

    Min Wang, Liyi Liu, Jia Wang & Chunyin Zhang

  4. Department of Breast Surgery, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, People’s Republic of China

    Jiayu Zhang

Authors
  1. Min Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiayu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liyi Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jia Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chunyin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

MW, JYZ, and CYZ contributed to the conception and design of the study. MW organized the database. MW, LYL, and JW performed the statistical analysis. MW wrote the first draft of the manuscript. JYZ, and LYL wrote sections of the manuscript. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Corresponding author

Correspondence to Chunyin Zhang.

Ethics declarations

Conflict of interest

M Wang, JY Zhang, LY Liu, J Wang and CY Zhang declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, M., Zhang, J., Liu, L. et al. The role of 68Ga-Pentixafor PET in multiple myeloma. Clin Transl Imaging 11, 453–463 (2023). https://doi.org/10.1007/s40336-023-00573-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40336-023-00573-5

Keywords

Search

Navigation